AIMS: Growth factor-induced repression of smooth muscle (SM) cell marker genes is an integral part of vascular SM (VSM) cell proliferation. This is partly regulated via translocation of extracellular signal-regulated kinase 1/2 (ERK1/2) to the nucleus which activates the transcription factor Elk-1. The mediators involved in ERK1/2 nuclear translocation in VSM cells are unknown. The aim of this study is to examine the mechanisms which regulate growth factor-induced nuclear translocation of ERK1/2 and gene expression in VSM cells. METHODS AND RESULTS: In cultured human VSM cells, phospholipase C (PLC)γ1 expression was required for platelet-derived growth factor (PDGF)-induced ERK1/2 nuclear translocation, Elk-1 phosphorylation, and subsequent repression of SM α-actin gene expression. The mechanisms of a role for PLCγ1 in ERK1/2 nuclear localization were further examined by investigating interacting proteins. The ERK1/2-binding phosphoprotein, protein enriched in astrocytes-15 (PEA-15), was phosphorylated by PDGF and this phosphorylation required activation of PLCγ1. In cells pre-treated with PEA-15 siRNA, ERK1/2 distribution significantly increased in the nucleus and resulted in decreased SM α-actin expression and increased VSM cell proliferation. Overexpression of PEA-15 increased ERK1/2 localization in the cytoplasm. The regulatory role of PEA-15 phosphorylation was assessed. In VSM cells overexpressing a non-phosphorylatable form of PEA-15, PDGF-induced ERK1/2 nuclear localization was inhibited. CONCLUSION: These results suggest that PEA-15 phosphorylation by PLCγ1 is required for PDGF-induced ERK1/2 nuclear translocation. This represents an important level of phenotypic control by directly affecting Elk-1-dependent transcription and ultimately SM cell marker protein expression in VSM cells.
AIMS: Growth factor-induced repression of smooth muscle (SM) cell marker genes is an integral part of vascular SM (VSM) cell proliferation. This is partly regulated via translocation of extracellular signal-regulated kinase 1/2 (ERK1/2) to the nucleus which activates the transcription factor Elk-1. The mediators involved in ERK1/2 nuclear translocation in VSM cells are unknown. The aim of this study is to examine the mechanisms which regulate growth factor-induced nuclear translocation of ERK1/2 and gene expression in VSM cells. METHODS AND RESULTS: In cultured human VSM cells, phospholipase C (PLC)γ1 expression was required for platelet-derived growth factor (PDGF)-induced ERK1/2 nuclear translocation, Elk-1 phosphorylation, and subsequent repression of SM α-actin gene expression. The mechanisms of a role for PLCγ1 in ERK1/2 nuclear localization were further examined by investigating interacting proteins. The ERK1/2-binding phosphoprotein, protein enriched in astrocytes-15 (PEA-15), was phosphorylated by PDGF and this phosphorylation required activation of PLCγ1. In cells pre-treated with PEA-15 siRNA, ERK1/2 distribution significantly increased in the nucleus and resulted in decreased SM α-actin expression and increased VSM cell proliferation. Overexpression of PEA-15 increased ERK1/2 localization in the cytoplasm. The regulatory role of PEA-15 phosphorylation was assessed. In VSM cells overexpressing a non-phosphorylatable form of PEA-15, PDGF-induced ERK1/2 nuclear localization was inhibited. CONCLUSION: These results suggest that PEA-15 phosphorylation by PLCγ1 is required for PDGF-induced ERK1/2 nuclear translocation. This represents an important level of phenotypic control by directly affecting Elk-1-dependent transcription and ultimately SM cell marker protein expression in VSM cells.
Authors: E Formstecher; J W Ramos; M Fauquet; D A Calderwood; J C Hsieh; B Canton; X T Nguyen; J V Barnier; J Camonis; M H Ginsberg; H Chneiweiss Journal: Dev Cell Date: 2001-08 Impact factor: 12.270
Authors: Sandra Pastorino; Hemamalini Renganathan; Maisel J Caliva; Erin L Filbert; John Opoku-Ansah; Florian J Sulzmaier; Joanna E Gawecka; Guy Werlen; Andrey S Shaw; Joe W Ramos Journal: FASEB J Date: 2010-03-30 Impact factor: 5.191
Authors: Kelin Wheaton; Sydney Aten; Lucas Sales Queiroz; Kyle Sullivan; John Oberdick; Kari R Hoyt; Karl Obrietan Journal: Eur J Neurosci Date: 2018-02-19 Impact factor: 3.386
Authors: Jenny S McKean; Fiona Murray; George Gibson; Derryck A Shewan; Steven J Tucker; Graeme F Nixon Journal: Cardiovasc Res Date: 2015-06-19 Impact factor: 10.787
Authors: Kim A Staats; Stephanie Humblet-Baron; Andre Bento-Abreu; Wendy Scheveneels; Alexandros Nikolaou; Kato Deckers; Robin Lemmens; An Goris; Jo A Van Ginderachter; Philip Van Damme; Chihiro Hisatsune; Katsuhiko Mikoshiba; Adrian Liston; Wim Robberecht; Ludo Van Den Bosch Journal: Hum Mol Genet Date: 2016-07-04 Impact factor: 6.150